Howard Hoffen
About Howard I. Hoffen
Howard I. Hoffen (age 61) is an independent director of EnerSys, serving since the company’s IPO in July 2004. He is Chairman, Chief Executive Officer and Managing Director (Partner) of Metalmark Capital LLC; previously he was Chairman & CEO of Morgan Stanley Capital Partners (2001–2004) and held various roles in Morgan Stanley’s private equity group since 1985. His core credentials span audit and financial oversight, risk management, and strategic planning, supported by an MBA from Harvard Business School and a BS from Columbia University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Metalmark Capital LLC | Chairman, CEO and Managing Director (Partner) | Founding member 2004–present | Private equity leadership; broad exposure to audit/financial, risk and strategy |
| Morgan Stanley Capital Partners | Chairman & CEO | 2001–2004 | Led private equity; deep experience in audit/financial reporting and compensation issues |
| Morgan Stanley Private Equity Group | Various roles | 1985–2001 | Private equity execution; extensive strategic planning background |
| Amplitude Healthcare Acquisition Corp. (SPAC) | Chairman | Oct 2019–Sept 2021 | SPAC that acquired Jasper Therapeutics (NASDAQ-listed) |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Playing For Change Foundation | Board Member | Not disclosed | Non-profit |
| Met Council | Board Member | Not disclosed | Non-profit |
| Dean’s Advisors, Harvard Business School | Advisor | Not disclosed | Academic advisory role |
| Current public company boards | None | — | Proxy lists “Other Public Boards: None” for Hoffen |
Board Governance
- Committee memberships: Member, Nominating & Corporate Governance Committee; served Nov 3, 2023–Aug 1, 2024 and continues thereafter (Wynter is Chair). Committee held four meetings in FY2025 .
- Not on Audit or Compensation Committees in FY2025; Audit Committee held five meetings; Compensation Committee held four meetings .
- Independence: Board determined all directors except the CEO are independent under NYSE standards; no material relationships with EnerSys beyond director compensation .
- Attendance and engagement: Board met five times in FY2025; each director attended at least 75% of Board and committee meetings for which they served .
- Board structure: Classified board. Hoffen is a Class III nominee in 2025; if elected, term runs to the 2028 annual meeting .
Fixed Compensation
- Program structure (FY2025):
- Annual cash retainer: $90,000 .
- Committee meeting fees: $1,500 per meeting .
- Committee Chair fees: $15,000 (Audit; Compensation; Nominating & Corporate Governance) .
- Independent Non-Executive Chair: additional $150,000 (50% deferred stock units, 50% cash) .
- Individual director compensation (FY2025):
Name Fees Earned in Cash Stock Awards Total Howard I. Hoffen $96,000 $155,030 $251,030 - Deferred Compensation Plan: Non-employee directors may defer cash fees into an investment account (401k-like options) or a stock unit account; company provides a 20% matching contribution in RSUs for stock unit deferrals, vesting quarterly over one year; matching accelerates at change-in-control; dividend equivalents credited; stock units payable in common shares; plan is non-qualified and unsecured .
Performance Compensation
- Performance metrics: Non-employee directors do not receive performance-based pay (no option awards, no non-equity incentive plan compensation, no above-market earnings on non-qualified deferred comp) in FY2025 .
- Equity grant mechanics:
Element FY2025 Detail Vesting Payout Notes Deferred Stock Units (DSUs) Grant-date fair value $155,000 per director Immediate vest at grant Shares payable 6 months after termination (unless further deferred) Dividend equivalents credited Director Plan Match 20% RSU match on stock unit deferrals Vests quarterly over 1 year Shares upon scheduled payout; accelerates upon change-in-control Dividend equivalents credited
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Current public company boards | None |
| Prior public company role | Chairman, Amplitude Healthcare Acquisition Corp. (SPAC), Oct 2019–Sept 2021; SPAC acquired Jasper Therapeutics (NASDAQ) |
| Compensation Committee interlocks | Company discloses no interlocking relationships requiring SEC disclosure; committee members were independent and had no material transactions with EnerSys |
Expertise & Qualifications
- Qualification highlights: Audit & Financial, Risk Management, Strategic Planning .
- Education: MBA, Harvard Business School; BS, Columbia University .
- Experience: Founding member of Metalmark Capital; prior Chairman & CEO of Morgan Stanley Capital Partners; extensive private equity board service .
Equity Ownership
| Holder | Shares Beneficially Owned | Percent of Class | Notes |
|---|---|---|---|
| Howard I. Hoffen | 45,183 | * (does not exceed 1%) | Includes DSUs and RSUs deferred under Director Plan; see footnote |
| Footnote (9) detail | — | — | Includes 42,268.2919 deferred stock units and 2,914.5649 vested RSUs deferred; all beneficially owned by Metalmark; Hoffen disclaims beneficial ownership except to the extent of pecuniary interest realized |
- Stock ownership guidelines: Non-employee directors expected to own shares equal to 5x annual Board cash retainer; each director achieved or is on track to achieve; hedging and pledging are prohibited .
Governance Assessment
-
Board effectiveness: Long-tenured independent director (since 2004) with deep private equity and capital markets expertise; serves on Nominating & Corporate Governance Committee, supporting board composition, succession and governance policy oversight (committee held 4 meetings in FY2025) .
-
Alignment and incentives: Director pay is majority equity via immediately vested DSUs with deferred payout, plus modest cash fees; Hoffen’s FY2025 stock awards exceeded cash fees ($155,030 vs. $96,000), improving alignment with shareholders .
-
Independence and attendance: Board determined independence; no material relationships; each director met at least the 75% attendance expectation; executive sessions of non-management directors are held periodically .
-
Potential conflicts and related-party exposure: Footnote indicates Hoffen’s DSUs and deferred RSUs are beneficially owned by Metalmark, with Hoffen disclaiming beneficial ownership except for pecuniary interest; while the Board affirms independence and no material relationships, this arrangement may warrant monitoring for perceived alignment dilution given the firm’s beneficial ownership of awards .
-
RED FLAGS:
- Deferred equity beneficially owned by Metalmark (disclaimed by Hoffen): potential optics risk on personal “skin-in-the-game” vs. firm-level ownership .
- Long tenure (since 2004): some investors view extended tenure as a potential independence softening, though NYSE independence affirmed and no related-party transactions disclosed .
-
Risk mitigants: Strict hedging/pledging prohibition; robust ownership guidelines (5x cash retainer) with compliance/on-track status; independent committees with clear charters; use of independent compensation consultant (FW Cook) and peer benchmarking for director compensation; regular executive sessions .